Back to top

Image: Bigstock

Is Dillard's (DDS) Stock a Solid Choice Right Now?

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is Dillard's, Inc. (DDS - Free Report) . This is because this security in the Retail - Regional Department Stores space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Retail - Regional Department Stores space as it currently has a Zacks Industry Rank of 20 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Dillard’s is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Dillard's, Inc. Price and Consensus

In fact, while current quarter earnings estimates have moved from a loss of 53 cents per share to a loss of 41 cents per share over the past month, current year estimates have risen from $6.05 per share to $6.13 per share. This has helped DDS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Dillard’s. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Dillard's, Inc. (DDS) - free report >>

Published in